PHARMACEUTICAL MARKET INDIA 2014-2020

PHARMACEUTICAL MARKET INDIA 2014-2020, Formulations, Active Pharmaceutical Ingredients (APIs), Contract Research and Manufacturing Services (CRAMS), Biosimilars, Generics & Vaccines

This report describes the current therapeutics that are propelling the pharmaceutical and biotechnology markets in India. It examines the current economic climate and how India compares to other emerging markets and also evolved markets such as the US and Europe. Current developments relating to patent expirations, government funding, and regulations are discussed. The emerging trends that appear in key sub-markets such as generics, oncology, cardiovascular, diabetes and vaccines are elucidated and analysed. 

This study reveals market figures of the overall Indian pharmaceutical market and sub-markets. It is supported by 333 figures and tables over 183 pages and the reader has the opportunity to re-use and referene these exhibits in their own reports and presentations. Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry.

The study also provides a comprehensive financial and product review of key players in the pharmaceutical and biotechnology industry in India. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. 

In summary, the Indian biopharmaceutical market has huge opportunities for growth. This industry will significantly affect the international healthcare market and has enormous potential for investment. 

Pharmaceutical Manufacturers & Distributors (UK) - Industry Report

Abstract
Plimsoll Publishing's PHARMACEUTICAL MANUFACTURERS & DISTRIBUTORS (UK) Analysis provides a detailed overview of the PHARMACEUTICAL MANUFACTURERS & DISTRIBUTORS (UK) market and delivers a comprehensive individual analysis on the top 440 companies, including ACCORD HEALTHCARE LTD, ALLERGY THERAPEUTICS (UK) LTD and ARCHIMEDES PHARMA UK LTD.
Description
Plimsoll's UK PHARMACEUTICAL MANUFACTURERS & DISTRIBUTORS (UK) analysis is the most definitive and accurate study of the UK PHARMACEUTICAL MANUFACTURERS & DISTRIBUTORS (UK) sector in 2013. The report is split into two sections and uses both a written and graphical analysis - analysing the 440 largest PHARMACEUTICAL MANUFACTURERS & DISTRIBUTORS (UK) companies. The PHARMACEUTICAL MANUFACTURERS & DISTRIBUTORS (UK) report contains the most-up-to-date financial data and Plimsoll applies these figures to create their unique and authoritative analysis. Indeed, the first section thoroughly scrutinises the market and this section includes the following: o Best Trading Partners: These are companies that are winning in both sales and financial strength - for example BIOGEN IDEC LTD has been ranked as a best trading partner in the industry. o Sales Growth Analysis: This section reviews the fastest growing and fastest shrinking company - for example SHARP CLINICAL SERVICES (UK) LTD is among the fastest growing. o Profit Analysis - Analysis of gross profit and pre-tax profit over the last ten years and a profitability summary comparing profits in the industry against small, medium and large companies. o Market Size: Based on the largest 440 companies, this is a comparison between last year's market size and the most current figure. o Rankings: The top 50 companies ranked by: Market Share, Sales Growth, Gross Profit and Pre-tax Profit. o Best Performing Company: IPSEN BIOPHARM LTD, DR FALK PHARMA UK LTD have been recognised for their strong financial strength and excellent sales increases throughout 2012 and have received Plimsoll's Best Performing Company Award. The next section focuses on company analysis and provides an in-depth analysis of the largest companies within the PHARMACEUTICAL MANUFACTURERS & DISTRIBUTORS (UK) industry. Each business is analysed using Plimsoll's unequivocal model and culminates in the production of the Plimsoll Chart. The Plimsoll Model uses a series of charts to graphically analyse an individual company and measure its ability to achieve sales growth while maintaining financial strength. The Plimsoll Chart is a quick and dependable method of analysing a company's financial well-being. It's simple to understand: a rising line is good news and a falling line is bad news. Therefore, this company analysis will tell you if a company is: o Strong or heading for failure o Utilising their investments o Becoming burdened by debt o Getting the most from their resources The Plimsoll  PHARMACEUTICAL MANUFACTURERS & DISTRIBUTORS (UK) analysis also provides you with full business name and address, name and ages of directors and registration address.

GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-Development, Business Strategies, Industry Trends, and Pipeline Analysis)

Abstract
This is a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by 280 tables & figures over 232 pages. The oncology biomarker (globaland USA) market is presented as follows: o By Company (e.g., 23andMe, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD, FOUNDATION MEDICINE, GENOMIC HEALTH) o By Geography (Global, US) o By Sub-market (Global Biomarker Market, Cancer Biomarker Market, Global Cancer Profiling Technology Market )	edit
Description
"GLOBAL & USA CANCER BIOMARKER MARKET to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis)" by Kelly Scientific Publications is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment. Cancer biomarkers are molecular or genetic moieties (e.g., cells, proteins/peptides, genetic mutations, gene products, enzymes, or hormones) that not only are readily identifiable, but easily quantified in the lab setting. They function primarily to identify or correlate significantly with the severity or occurrence of a certain disease state. The rise in number of oncogenic biomarkers over the last number of years has massive potential in the healthcare industry and serves to propel both the personalized medicine and companion diagnostic markets. One of the most import aspects of biomarkers is their use to diagnose and assess the progress of disease states in patients. As quantitative markers, these agents also offer the ability to monitor response to certain drug treatments and so are important in the area of personalized medicine. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics will be more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine will reduce the frequency of adverse drug reactions and therefore have a dramatic impact on health economics. Developmental and diagnostic companies will benefit from lower discovery and commercialization costs and more specific market subtypes. This report describes the current technologies that are propelling the cancer biomarker and companion diagnostic market. It examines the current genetic diagnostic tests and companion diagnostic assays that are in use by the medical and pharmaceutical industry today. Current developments in personalized medicine and the pharmacogenomics revolution are discussed. The emerging trends that appear in the global market and the most developed market (US) are elucidated and analysed. This study reveals market figures of the overall biomarker market and the cancer biomarker space (2013-2018). Forecast projections and future growth rates are provided to give the reader a forthcoming perspective of this growing industry. The study also provides a comprehensive financial, business strategy and product review of key players in the cancer biomarker industry. Strategic drivers and restraints of this market are revealed and market opportunities and challenges are identified. In summary, the cancer biomarker and associated companion diagnostic market have huge opportunities for growth. This industry will revolutionize the healthcare system and will improve therapeutic effectiveness and reduce the severity of adverse effects. It has enormous potential for investment and the emergence of genetic-based in vitro diagnostics. Read more